

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
15 January 2004 (15.01.2004)

PCT

(10) International Publication Number  
**WO 2004/004817 A1**

(51) International Patent Classification<sup>7</sup>: **A61M 16/10**,  
16/12

(AT). MÜLLNER, Rainer [AT/AT]; Friedhofstrasse 13a,  
A-2351 Wr. Neudorf (AT).

(21) International Application Number:  
PCT/EP2003/006856

(74) Agent: DÖRRIES, Hans, Ulrich; Triftstr. 13, 80538  
München (DE).

(22) International Filing Date: 27 June 2003 (27.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
102 30 165.4 4 July 2002 (04.07.2002) DE


(71) Applicant (for all designated States except US): **INO  
THERAPEUTICS GMBH** [AT/AT]; Wolfholzgasse 28,  
A-2345 Brunn am Gebirge (AT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PI, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

[Continued on next page]

(54) Title: METHOD AND APPARATUS FOR THE ADMINISTRATION OF CO



(57) Abstract: The present invention relates to a method and apparatus for the administration of carbon monoxide (CO) to a patient. It allows the safe and effective use of carbon monoxide as a medicament.

→ Information flow  
⇒ Mass flow



SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

**Declaration under Rule 4.17:**

— as to the identity of the inventor (Rule 4.17(i)) for the following designations AF, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PI, PT, RO, RU, SC, SD, SE, SG, SK, SI, SJ, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ,

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

5    Technical field

The present invention relates to a method and an apparatus for the administration of carbon monoxide to patients. More specifically, it relates to the controlled administration of carbon monoxide to a patient in order to achieve safe and effective use  
10   of carbon monoxide as a medicament.

Background of the invention

15   The therapeutic use of carbon monoxide (CO) has recently been the focus of scientific interest, and the medicinal effects of CO have been analyzed in animal experiments. Fujita et al. pointed to a link between CO and prevention of ischemic injury in mice, "Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by depression of fibrinolysis", *Nature medicine*, May 2001, 7, (5); p598-604. Chapman et  
20   al. in "Carbon monoxide attenuates aeroallergen-induced inflammation in mice", *American Journal of Physiology*, Jul 2001, 281;(1); pL209-16 further pointed to an immunoregulatory role of CO in aeroallergen induced inflammation in mice.

WO 98/13058 (Pinsky et al.) claims methods of treating ischemic disorders comprising  
25   administering to the subject carbon monoxide gas in a sufficient amount over a sufficient period of time. Animal experiments using rats treated with CO prior to lung harvesting and transplantation of the harvested lung are reported. However, the application fails to provide any useful information as to how CO may be safely and effectively administered to individuals suffering from ischemia in a manner that ensures  
30   that the individual benefits from such treatment without being at risk of suffering from CO intoxication.

Gas-supply systems for the treatment of patients with controlled doses of medical gases are known in the art. For example, European patent 0 621 051 discloses an apparatus for the monitored metering of nitric oxide (NO) into the respiratory air of a patient.

- 5 WO 98/31282, the disclosure of which is incorporated herein by reference, discloses a controlled gas-supply system, in which one or several gases are added to the respiration gas of a patient at varying proportions by means of a control device, which device may offer a program control, a sensor control, or a combined sensor/program control. However, the application is silent regarding the possibility to administer a carbon  
10 monoxide containing gas. Consequently, it fails to provide any guidance as to how CO may be safely and effectively administered to individuals while avoiding the risk of CO intoxication.

- A method or an apparatus for administration of therapeutic amounts of CO to an  
15 individual, human or animal, is not known from the prior art. Furthermore, a method and an apparatus whereby carbon monoxide can be safely and effectively administered to an individual is not known.

- It is therefore an object of the present invention to provide a method and an apparatus  
20 for the safe and effective administration of carbon monoxide to patients. It is a further object to provide a method and an apparatus for such administration which avoid the risks which follow from the toxicity of carbon monoxide in humans and animals. Another object of the invention is to provide a method and apparatus for the administration of carbon monoxide to patients whereby the gas is administered in an  
25 effective way to achieve the best possible therapeutic effect of the gas.

These and further objects are solved by the methods and apparatuses as herein described and claimed.

30 Summary of the Invention

Accordingly, in a first embodiment of the present invention, a method for administering carbon monoxide to a patient is provided, comprising the steps of

- a) administering exogenous carbon monoxide to the patient,

- b) determining the concentration of carbon monoxide in the patient's blood,
  - c) comparing the actual concentration of carbon monoxide in the blood with a preset, desired value; and
  - d) subsequently adjusting the amount of carbon monoxide delivered to the patient to
- 5 obtain a concentration in the patient's blood corresponding to the preset desired value; and optionally repeating steps b) – d).

10 In another aspect, the present invention provides an apparatus for administering carbon monoxide to a patient, the apparatus comprising a delivering unit for administering carbon monoxide to the patient, a carbon monoxide source, a dosing unit, sensor means for determining the concentration of carbon monoxide in the blood, and control means for regulating the dosing unit depending on feedback from the sensor unit.

15 In another aspect, the present invention provides in another aspect the use of a delivering unit, a carbon monoxide source, a dosing unit for administering carbon monoxide to a patient, a sensor means for determining the concentration of carbon monoxide in the blood, a control means for regulating a carbon monoxide dosing unit, or a filter unit suitable to remove excess carbon monoxide from expired gas, said filter

20 being a physical or chemical filter, in any of the afore-mentioned methods according to the invention.

Finally, the present invention relates to the use of carbon monoxide or a carbon monoxide donor for the preparation of a medicament, for example an inhalable

25 medicament, for the treatment of ischemia related conditions or the regulation of the immune response in a patient in need thereof by one of the methods according to the present invention.

30 Brief Description of the Figures

Figure 1 shows a scheme of an apparatus according to a preferred embodiment of the present invention.

Figure 2 shows dosing curves for CO and O<sub>2</sub> in correlation with the concentration of carboxyhemoglobin in the patient's blood (straight line) and a preset value for the carboxyhemoglobin concentration (dotted line) in an embodiment according to the present invention.

5

#### Detailed Description

According to the invention, a carbon monoxide source comprises suitable storage units  
10 for carbon monoxide in gaseous form (optionally as a mixture comprising further gases, e.g., nitrogen, carbon dioxide, oxygen, argon, helium, sulfur hexafluoride, gaseous hydrocarbons, xenon), or in liquid form, or as a solution (e.g., in saline). Alternatively, the carbon monoxide may be provided in the form of a carbon monoxide donor. Said donor may comprise a gas, a liquid, a solid, or a solution.

15

A delivering unit according to the invention comprises medical devices suitable for the administration of gaseous or liquid medicaments to a patient. Those medical devices are known in the art and comprise, but are not limited to, e.g., a respirator, a ventilator, a nose cannula, a face mask (for the administration of gases), devices for the controlled  
20 administration of liquids by injection or infusion (for intravenous administration), devices for the controlled administration of liquids and/or gases by enema (for rectal administration), nebulizers (for the administration via nebulizing CO-releasing compounds and CO-releasing smoke) and conventional insufflation equipment (for the administration of gases via insufflation). It will further be understood that a delivering  
25 unit according to the invention may comprise means for the connection to a carbon monoxide source and/or a dosing unit, e.g., tubes, plug-ins, contacts, clamps and the like, the specific technical nature of these means depending on the delivering unit, the dosing unit and the carbon monoxide source actually employed.

30 A dosing unit according to the invention comprises technical means for the regulation of the quantity of carbon monoxide which is delivered from the carbon monoxide source to the delivering unit (and thus to the patient), wherein the quantity may be varied during the application. The technical nature of the dosing unit depends on the delivering unit and the carbon monoxide source actually employed. Suitable dosing units comprise, but

are not limited to, e.g., one or several controllable valves or valve combinations or a relief valve.

Sensor means according to the invention comprises technical means for the determination of the concentration of carbon monoxide in the blood of a patient. Suitable sensor means comprise, but are not limited to, means for the measurement of carboxyhemoglobin or oxyhemoglobin or enzyme activity in the patient's blood by spectroscopic, polarographic or other methods, as well as means for the measurement of carbon monoxide in the gas mixture expired from a patient by spectroscopic methods or gas chromatography.

A control unit according to the invention comprises technical means for comparing the actual CO blood concentration directly or indirectly determined by the methods described herein with a preset desired value, and subsequently causing the dosing unit to regulate the amount of carbon monoxide delivered to the patient to obtain a concentration in the patient's blood corresponding to the preset desired value. The control unit may perform a program control, a sensor control, or a combined program/sensor control. Suitable control units comprise, but are not limited to, a conventional CPU (e.g., a discrete comparator, consisting of transistors or OP-amplifiers which compare the levels of a preset CO level and the CO level in the patient's blood).

Apparatuses and devices for the application of medicaments to a patient, which comprise at least two or more units as described above, are commercially available. It will be understood that such apparatuses and devices may also be employed for the purposes of the present invention. It will further be understood that the present invention also comprises the use of devices wherein at least two units as described above are combined into one single device. For example, a conventional respirator suitable for the present invention may serve as a dosing unit and as a delivering unit, although it is normally understood to be a single apparatus.

The present invention provides a method and apparatus for the safe administration of carbon monoxide to patients, wherein the concentration of carbon monoxide in the

patient's blood is continuously monitored during the process, and the administration is continuously adjusted according to the current concentration.

For that purpose, after the first administration of carbon monoxide the concentration of carbon monoxide in the patient's blood is determined, and the actual concentration is compared to a preset, desired value. If the actual concentration is lower than the preset value, the carbon monoxide dose in the subsequent step(s) of administration is enhanced. If the actual concentration is higher than the preset value, the carbon monoxide dose in the subsequent step(s) of administration is reduced.

10

A preset value for the concentration of CO in the patient's blood according to this invention is between about 0.5 % to 50 %, preferably between 5 % and 20 %, more preferably between 5 % and 15 %, and most preferably about 8 % ( all values calculated as carboxyhemoglobin per total hemoglobin).

15

The preset value may also comprise a range of concentration, limited by a maximum value and a minimum value. If the concentration of carbon monoxide in the blood is outside this range, then the dosing will be adjusted.

Alternatively, in order to control and adjust the CO concentration in the patient's blood, it is also possible to reduce or enhance the concentration of oxygen in the patient's breathing gas, since the concentration of carbon monoxide and oxygen in the blood are connected via an equilibrium. Finally, the steps of administering, determining the CO blood concentration and adjusting the amount of carbon monoxide delivered to the patient may be repeated several times.

Several methods are known in the art that are suitable for the determination of carbon monoxide in the blood of a patient. One preferred method is to measure the concentration of carboxyhemoglobin (HbCO) in the blood. Such measurements can be performed in a non-invasive manner, e.g., by spectroscopic methods, e.g., as disclosed in U.S. 5,810,723 and 6,084,661 or in British patent No. GB 2,333,591, the disclosure of both documents being incorporated herein by reference. Invasive methods which include the step of taking a blood sample are, of course, likewise suitable.

30



Since an equilibrium exists between the concentrations of oxygen and carbon monoxide in the blood, another preferred method is to measure the concentration of oxygen in the blood (oxymetry) and to calculate the carbon monoxide concentration from the equilibrium constant. The oxymetric measurement can be performed in a non-invasive manner by spectroscopic determination of oxyhemoglobin concentration in the blood, e.g., as disclosed in European patent No. 0 524 083 or U.S. 5,413,100, the disclosure of both documents being incorporated herein by reference. Another possibility for oxymetric measurements is the employment of polarographic methods which are well-established in the art. Again, invasive methods which include the step of taking a blood sample are, of course, likewise suitable to determine the concentration of oxygen in the blood.

Although the best-known reaction of carbon monoxide incorporated in a human or animal body is the formation of carboxyhemoglobin, it can also interact with other biological targets such as enzymes, e.g. cytochrome oxidase or NADPh. Activity measurements regarding these enzymes may thus also be employed for calculating the carbon monoxide concentration in the blood.

There is an equilibrium regarding the distribution of carbon monoxide between blood and the respired gas mixture. Another preferred method for determining the blood concentration of CO is thus the measurement of the carbon monoxide concentration in the expired air of a patient. This measurements may be done by spectroscopic methods, e.g., by ultra red absorption spectroscopy (URAS), or by gas chromatography. This method of determination is well-established in medical art for the determination of the diffusing capacity of the lungs of a patient; an apparatus for those tests is disclosed in U.S. patent No. 5,022,406, the disclosure of which is incorporated herein by reference. Alternatively, the measurements of CO concentration may be carried out by electrochemical methods known in the art.

As mentioned above, the high toxicity of carbon monoxide makes it necessary to ensure that the dosage of CO is always kept at levels that ensure sufficient metabolic activity in the individual treated. The present invention provides for the first time methods and apparatuses that avoid the risk of CO intoxication. Preferably, the concentration of CO in the blood is determined by at least two independent methods of measurement. More

preferably, the first method of measurement is the spectroscopic measurement of carboxyhemoglobin in the patient's blood, which may be combined with the spectroscopic measurement of oxyhemoglobin or the measurement of the CO concentration in the expired air from the patient.

5

Additionally, it is preferred that the measuring unit(s) is connected to an alarm unit, which is activated if, e.g., the carbon monoxide concentration in the patient's blood exceeds a preset desired value. Additionally, in the case described above wherein at least two independent methods of measurement are employed, the alarm unit may be  
10 activated if the carbon monoxide concentration derived by the first method shows a difference to that derived by the second method that exceeds a preset desired value.

When using carbon monoxide as a medicament as described above, it has to be considered that the carbon monoxide is eliminated from the patient mainly by expiration  
15 via the lungs, resulting in an enhanced concentration of carbon monoxide in the surrounding air, if the carbon monoxide is not removed from the expired air. Accordingly, in a preferred embodiment, the method and apparatus of the present invention employ a filter device to remove CO from the air expired by the patient. The filter device may remove the carbon monoxide by physical effects, e.g., by dissolving  
20 the CO in a suitable solvent or adsorbing CO on a suitable adsorber material, or by chemical effects, e.g., by oxidation of CO to CO<sub>2</sub> by using a suitable catalyst. Filter devices as described above are known in the art, e.g., molecular separators, gas purifiers or wet gas cleaners may be employed.

25 An example of an apparatus according to the present invention is shown in Figure 1, wherein the apparatus comprises a CO source (10), which is connected to a delivering unit (30). The mass flow between the CO source (10) and the delivering unit (30) is controlled by a dosing unit (20). The CO is administered to the patient by the delivering unit (30), while the air expired by the patient is cleaned by passing it through the filter  
30 unit (80). The concentration of carbon monoxide in the patient's blood is independently measured by two sensor units (50, 60), which are both independently connected to the alarm unit (70). Both sensor units are furthermore independently connected to the control unit (40), which regulates the dosing unit (20) in order to ensure a controlled

delivery of CO to the patient, which depends on the actual concentration of CO in the patient's blood.

Carbon monoxide at normal conditions is a gaseous compound. The admixing of carbon  
5 monoxide into the breathing air (or a breathing gas mixture different from air) for  
inhalation of a patient may thus be considered to be a convenient manner of application  
according to the invention. However, carbon monoxide may also suitably be  
administered for the purposes of this invention by insufflation or as a solution in  
pharmaceutically acceptable liquids via intravenous or rectal application. Alternatively,  
10 it can be administered in the form of carbon monoxide donor compounds, which release  
the CO after the application. A donor compound suitable for this invention may  
comprise either a carrier, e.g., extracorporeal (synthetic) carboxyhemoglobin, or a  
compound that is metabolised to CO, e.g. methylene chloride ( $\text{CH}_2\text{Cl}_2$ ) or heme  
oxygenase.

15

For the administration of the carbon monoxide containing gas mixture a conventional  
respirator apparatus, a ventilator, a face mask or a nose cannula may be employed.

The carbon monoxide may be administered to the patient in a continuous or  
20 discontinuous manner. In particular, a pulsed administration is suitable according to the  
present invention, in particular wherein the pulses are combined to pulse sequences. If  
the carbon monoxide is administered by admixing gaseous carbon monoxide into the  
breathing gas mixture of a patient, the pulses may be triggered by inspiration or  
expiration. Additionally, the number and length of the single pulses may be determined  
25 by the current concentration of CO in the patient's blood. An example for a variation of  
the pulse length depending on the CO concentration is given in Figure 2. Alternatively,  
the regulation of the amount of CO in the breathing gas mixture may be performed by  
varying the CO flow when the CO is administered in a continuous manner. The patient  
may breath spontaneously or artificially.

30

Additionally, dosing algorithms may be employed in order to obtain different dosages at  
different times of the therapy. For example, a high concentration of CO may be  
administered at the beginning of the treatment, a (lower) constant concentration may be  
administered during therapy, while at the end the concentration is again lowered. The

administered dosages are thus dependent on the duration of the therapy and the actual concentration of CO in the blood.

Claims

1. A method for administering carbon monoxide to a patient, comprising the steps of
  - a) administering exogenous carbon monoxide to the patient,
  - b) determining the concentration of carbon monoxide in the patient's blood,
  - c) comparing the actual concentration of carbon monoxide in the blood with a preset, desired value; and
  - d) subsequently adjusting the amount of carbon monoxide delivered to the patient to obtain a concentration in the patient's blood corresponding to the preset desired value; and optionally repeating steps b) – d).
2. The method according to claim 1 wherein the concentration of carbon monoxide in the blood is determined by a method selected from the group consisting of: measuring the concentration of carboxyhemoglobin (HbCO) in the blood, measuring the concentration of oxyhemoglobin (HbO<sub>2</sub>) in the blood, measuring the activity of enzymes in the blood; and measuring the CO content of the air expired by the patient.
3. The method according to claim 2 wherein the carboxyhemoglobin (HbCO) is determined by non-invasive measurement, or is determined from a blood sample.
4. The method according to claim 2 wherein the measurement of the oxyhemoglobin (HbO<sub>2</sub>) in the blood is carried out by oxymetry.
5. The method according to claim 2 wherein the measurement of the composition of the expired air is carried out by spectroscopic or electrochemical methods.
6. The method according to any one of the preceding claims wherein the carbon monoxide is delivered to a patient as a pure gas, in a gas mixture, dissolved in a fluid, or by administering a carbon monoxide donor.

7. The method according to any one of the preceding claims wherein the carbon monoxide is delivered to the patient through inhalation, insufflation, intravenously, or rectally.
- 5 8. The method according to claim 6 wherein the carbon monoxide containing gas mixture is administered by way of admixing it into the breathing air of a patient.
9. The method according to claim 7 or 8 wherein the carbon monoxide is delivered for inhalation in pulses, wherein the pulses may be inspiration and/or expiration  
10 triggered.
10. The method according to claim 8 or 9 wherein the concentration of carbon monoxide in the blood is controlled by the oxygen content of the breathing gas.
- 15 11. The method according to claim 8 wherein the administration of carbon monoxide is performed via sequences of pulses, wherein the number and length of the pulses in each sequence and/or the number of sequences is regulated depending on the determination of the concentration of carbon monoxide in the blood.
- 20 12. The method according to any one of the preceding claims wherein the patient is spontaneously breathing or artificially breathing.
13. The method according to any one of the preceding claims wherein the concentration of carbon monoxide in the blood is determined by at least two separate methods of  
25 measurement.
14. An apparatus for administering carbon monoxide to a patient, the apparatus comprising a delivering unit, a carbon monoxide source, a dosing unit for administering carbon monoxide to the patient, sensor means for determining the  
30 concentration of carbon monoxide in the blood, and control means for regulating the dosing unit depending on feedback from the sensor unit.
15. The apparatus according to claim 14, wherein the carbon monoxide source is a source providing carbon monoxide gas, optionally in a mixture with one or more

other gases, and wherein the dosing unit is for administering the carbon monoxide gas or the carbon monoxide containing gas mixture into the breathing gas mixture of a patient.

- 5 16. The apparatus according to any one of claims 14 or 15 wherein the delivering unit is selected from the group consisting of a respirator, a ventilator, a face mask, and a nose cannula.
- 10 17. The apparatus according to any one of claims 14 to 16 characterised in that the apparatus comprises at least two independently working sensor means for the determination of carbon monoxide in the blood.
- 15 18. The apparatus according to any one of claims 14 to 17 wherein at least one of the sensor means is connected to an alarm unit.
- 20 19. The apparatus according to any one of claims 14 to 18 wherein the sensor means are selected from the group consisting of: means for measuring the concentration of carboxyhemoglobin (HbCO), means for measuring the concentration of oxyhemoglobin (HbO<sub>2</sub>) in the blood, means for measuring the activity of enzymes in the blood; and means for measuring the composition of the air expired by the patient.
- 25 20. The apparatus according to any one of claims 14 to 19 further comprising a filter unit through which the air expired by the patient is passed in order to remove excess carbon monoxide from the expired gas, wherein the filter is a physical or a chemical filter.
- 30 21. Use of a delivering unit, a carbon monoxide source, a dosing unit for administering carbon monoxide to a patient, a sensor means for determining the concentration of carbon monoxide in the blood, a control means for regulating a carbon monoxide dosing unit, or a filter unit suitable to remove excess carbon monoxide from expired gas, said filter being a physical or chemical filter, in a method according to any one of claims 1-13.

1 / 2




Fig. 1



2/2




Fig. 2

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/06856

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61M16/10 A61M16/12

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61M A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                               | Relevant to claim No. |
|------------|--|-----------------------|
| X          | GB 1 581 482 A (DRAEGERWERK AG)  | 14-16, 20             |
| Y          | 17 December 1980 (1980-12-17)<br>page 2, line 83 - line 87<br>page 3, line 13 - line 113<br>figure<br>---<br>-/- | 18, 19                |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

7 October 2003

Date of mailing of the international search report

27/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Borowski, A

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/06856

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| Y          | WO 01 41856 A (PULMONOX MEDICAL CORP<br>;MILLER CHRIS C (CA); MILLER JOHN W R<br>(CA);) 14 June 2001 (2001-06-14)   | 18                    |
| A          | page 1, line 5 - line 26<br>page 2, line 31 -page 3, line 10<br>page 5, line 12 - line 27<br>page 6, line 22 - line 28<br>page 7, line 5 - line 10<br>page 7, line 26 - line 30<br>page 13, line 16 - line 23<br>page 14, line 11 -page 15, line 2<br>page 18, line 21 - line 29<br>claims 1-20; figure 1 | 14-16                 |
| Y          | EP 0 524 083 A (EFFETS BIOLOGIQUES<br>EXERCICE) 20 January 1993 (1993-01-20)<br>cited in the application<br>whole document  | 19                    |
| A          | US 5 979 443 A (DINGLEY JOHN)<br>9 November 1999 (1999-11-09)<br>column 3, line 25 -column 4, line 46<br>column 8, line 4 - line 8  | 14                    |
| A,P        | WO 02 056931 A (TYOMKIN EVGENY ;TYOMKIN<br>TATYANA (IL); AUTOMED AUTOMATIC DOSAGE<br>SYS) 25 July 2002 (2002-07-25)<br>page 8, line 13 - line 25<br>page 9, line 3 - line 15<br>claims 1-7,12-17; figures 1-3   | 14-20                 |

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 03/06856

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-13, 21  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy: A method for administering carbon monoxide to a patient.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 03/06856

| Patent document<br>cited in search report |   | Publication<br>date | Patent family<br>member(s)   | Publication<br>date  |
|---|---|---------------------|--|--|
| GB 1581482                                | A | 17-12-1980          | BE 847039 A1<br>CH 618602 A5<br>DE 2744327 A1<br>SE 432879 B   | 31-01-1977<br>15-08-1980<br>13-04-1978<br>30-04-1984   |
| WO 0141856                                | A | 14-06-2001          | CA 2292128 A1<br>AU 2133201 A<br>WO 0141856 A2<br>US 2002178783 A1   | 08-06-2001<br>18-06-2001<br>14-06-2001<br>05-12-2002   |
| EP 0524083                                | A | 20-01-1993          | FR 2679337 A1<br>AT 134850 T<br>CA 2074029 A1<br>DE 69208760 D1<br>EP 0524083 A1<br>JP 5228129 A<br>US 5413100 A | 22-01-1993<br>15-03-1996<br>18-01-1993<br>11-04-1996<br>20-01-1993<br>07-09-1993<br>09-05-1995 |
| US 5979443                                | A | 09-11-1999          | AU 6011196 A<br>DE 69606405 D1<br>DE 69606405 T2<br>DK 830166 T3<br>EP 0830166 A1<br>WO 9641651 A1               | 09-01-1997<br>02-03-2000<br>07-09-2000<br>24-07-2000<br>25-03-1998<br>27-12-1996               |
| WO 02056931                               | A | 25-07-2002          | WO 02056931 A2   | 25-07-2002   |